Neekesh V. Dharia, MD PhD

"It's never over. You continue with your scans, and you wait and you hold your breath, but that's why we do this." Lisa Scherber on Max Mitchell, a 12-year-old diagnosed with Ewing Sarcoma at age 5 and has persevered through treatment ever since. @TheJimmyFund | @TomCaron

@DocSacher presenting on #KRAS targeting G12C with oral TKI GDC6036 at the oral session #LCSM #WCLC22 @IASLC @KRASKickers

Dr. @DocSacher presents impressive data on GDC-6036 in #KRAS G12C NSCLC - clearly active with confirmed RR 46% and some quite durable responses. Field getting more crowded. #WCLC22

The KRAS G12C inhibitor GDC-6036 conveys confirmed ORR 46%, early reported duration of response and depth of responses need further follow-up, excelente présentation by Dr. Adrian Sacher @IASLC #WCLC22

GDC6036 covalent KRAS G12C. FIH data NSCLC cohort. Prior G12C therapy excluded. N=59. Nausea vomiting and diarrhea commonest AEs usually low grade. 7% g3 ALT elevation. Expansion dose 400mg OD. cORR 46%. Impressive spider plots. Looking forward to more mono & combo data #WCLC22

First data of GDC-6036, a KRAS G12C inhibitor. Confirmed ORR 26/57 (46%) but note that this might be higher if limited to patients treated at the R2PD (400mg). Predominant GI and liver tox, seems manageable. Promising but enough to get PFS>10 months? #WCLC2022

Online Now: TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma dlvr.it/S4hKVy

Congratulations to post-doc @alexseong24 and team on the publication of this exciting work at @Cancer_Cell!

Very excited that my work on TRIM8 in #Ewing sarcoma is now published in @CancerCell cell.com/cancer-cell/fu… #openaccess#pediatric#cancer#selective#dependency#fusion#oncoprotein#stability#degradation @DanaFarber @DFBC_PedCare

Recently published #OnlineFirst: Selective modulation of a pan-essential protein as a therapeutic strategy in cancer. @DanaFarber @BostonChildrens @BroadInstitute #SyntheticLethality bit.ly/3tHcXkP

By performing genome-scale screening in childhood tumours, scientists have uncovered clues to the tumours’ potential Achilles heels — but have also learnt that paediatric cancers have unique vulnerabilities not present in adult tumours. #ResearchHighlight go.nature.com/3mAxq88

ICYMI @nature #ResearchHighlight Quirks of kids’ cancers are revealed — and could shape hunt for drugs nature.com/articles/d4158… 😍Original article in @NatureGenet here: nature.com/articles/s4158…

Genome-scale CRISPR–Cas9 screening of 82 paediatric cancer cell lines were subjected reveals genes required for cell survival, leading to a 1st-gen pediatric cancer dependency map. Vulnerabilities observed were often distinct from those of adult cancers: nature.com/articles/s4158…

A new study published in @NatureGenet by researchers from @DFBC_PedCare and @broadinstitute is the first comprehensive view of the differences in genetic dependencies between pediatric and adult cancers (via @medical_xpress): ms.spr.ly/6013VuV41 Cc: @NeekeshD #childhoodcancer

A first-generation pediatric cancer dependency map (Dharia et al.) go.nature.com/3tIbqe0

.@CancerDepMap scientists and colleagues have mapped genetic dependencies in pediatric cancers and found many that are unique to these cancers -- suggesting new avenues for drug development. broad.io/PediatricDepMap

Targeted treatments exist for only ~ 1/4 of children with #cancer. That’s poised to change with the Pediatric Cancer Dependency Map, just published in Nature Genetics: ms.spr.ly/6011VOQDN cc: @DFBC_PedCare

Pediatric cancer was underrepresented in @CancerDepMap. We teamed up with pediatric cancer investigators to profile cell lines from 13 pediatric tumors. Excited to share the results of the analysis led by @NeekeshD. 1/5 nature.com/articles/s4158…

“Max deserves a cure. He’s just an eight year old kid who wants to play ball.” -Michael, dad of @DanaFarber patient Max, 8 ⚾️ Help us #KCANCER with the @RedSox! jimmyfund.gives/c6a4h

Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry (Durbin et al.) go.nature.com/2nUccVA